A preparation of autologous human T-lymphocytes engineered to express chimeric T-cell receptors (chimeric antigen receptors or CARs) targeting the tumor-associated antigens (TAAs) CD19 and CD22 and fused to as of yet not fully elucidated co-stimulatory domains, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous bispecific CD19/CD22-targeted CAR-T cells GC022 bind to CD19 and CD22 on the surface of, and induce selective toxicity against, tumor cells expressing CD19 and CD22. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are overexpressed on malignant B-cells.